Sunshine Biopharma Files $7M Best-Efforts Offering with Series D Warrants at $0.6876
SBFM is trading near its 52-week low of $0.667 (0.0% above the low) on light trading volume (0.2× avg).
Summary
Sunshine Biopharma registered a $7 million best-efforts offering of units with Series D Warrants at $0.6876 per unit, adding significant dilution risk while the company trades near its 52-week low and faces Nasdaq delisting. The offering is priced at $0.6876 per unit, a modest discount to the current $0.6495 market price, with each unit including a Series D Warrant.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — The offering is priced at $0.6876 per unit, a modest discount to the current $0.6495 market price, with each unit including a Series D Warrant.
- The offering is a best-efforts deal.
Key Events · Financing and Capital Events · SBFM
-
Updated · · Dow Jones Newswires
$7M Best-Efforts Offering Filed
Company registered up to 10,180,337 Common Units and 10,180,337 Pre-Funded Units at $0.6876 per unit, each with two Series D Warrants, for total potential proceeds of $7 million. The offering is priced at $0.6876 per unit, a modest discount to the current $0.6495 market price, with each unit including a Series D Warrant.
-
Massive Potential Dilution
If all units are sold, shares outstanding would rise from 4.31 million to 14.49 million, and Series D Warrants could add up to 40.7 million more shares upon exercise.
-
Series D Warrant Terms
Warrants are exercisable at $0.6876 for five years, with a Share Combination Event adjustment that could lower the exercise price to $0.3438 if a reverse split occurs.
-
Nasdaq Delisting Risk
Company discloses it does not meet the proposed $5 million Nasdaq Market Value of Listed Securities requirement and is subject to immediate delisting notice until June 2027.
Analysis · SBFM · Life Sciences
Sunshine Biopharma is raising up to $7 million through a best-efforts offering of units priced at $0.6876, the last reported sale price on October 1, 2026. Each unit includes one share (or pre-funded warrant) and two Series D Warrants exercisable at $0.6876 for five years. The deal is highly dilutive: if all 10.18 million units are sold, the share count would rise from 4.31 million to 14.49 million, and the Series D Warrants could add up to 40.7 million more shares upon exercise. The company is trading near its 52-week low and faces Nasdaq delisting risk, making this a survival capital raise at a deeply depressed valuation. The Series D Warrants include a Share Combination Event adjustment that could lower the exercise price to $0.3438 if a reverse split occurs. The offering is priced at $0.6876 per unit, a modest discount to the current $0.6495 market price, with each unit including a Series D Warrant.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.67 to $24.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.